Medical diagnostics are the tests and technologies used to determine whether a person has a particular condition, how severe it is, how it is likely to progress, and how it is responding to treatment. They range from a blood count performed in a hospital laboratory to genomic sequencing of a tumour, from a bedside rapid test to a whole-body imaging study.

Diagnostics shape a large proportion of clinical decisions, yet no test is perfect. Understanding what a result means requires understanding how accurate the test is and how likely the condition was before the test was performed — a point that is widely underappreciated and that determines whether a positive result should be believed.

The Main Categories of Diagnostic Technology

Clinical Laboratory Testing

The largest volume of diagnostic activity takes place in clinical laboratories analysing blood, urine, and other samples. Clinical chemistry measures analytes such as electrolytes, glucose, and markers of organ function. Haematology examines blood cells and coagulation. Microbiology identifies pathogens through culture, staining, and susceptibility testing. Immunology and serology detect antibodies and antigens. Histopathology and cytology examine tissue and cell samples under the microscope, and remain the definitive method for diagnosing and classifying most cancers.

Molecular Diagnostics

Molecular methods detect and analyse nucleic acids. Polymerase chain reaction amplifies specific DNA or RNA sequences, allowing detection of very small quantities of pathogen or human genetic material; it underpins much modern infectious disease diagnosis. Next-generation sequencing reads large amounts of genetic sequence in parallel and is used in inherited disease diagnosis, tumour profiling, and pathogen characterisation. Techniques for detecting circulating tumour DNA in blood — often described as liquid biopsy — are used in oncology for mutation detection and monitoring, with applications and evidence varying considerably by cancer type and clinical purpose.

Imaging

Imaging modalities visualise anatomy and, in nuclear medicine, physiological function. X-ray, computed tomography, magnetic resonance imaging, ultrasound, and positron emission tomography each exploit different physical principles and therefore answer different clinical questions. Imaging is often complementary to laboratory testing rather than an alternative to it.

Physiological and Functional Testing

Some diagnostics measure how a system functions rather than examining a sample or an image: electrocardiography and cardiac monitoring, spirometry and lung function testing, electroencephalography, nerve conduction studies, and exercise testing.

Point-of-Care and Near-Patient Testing

Point-of-care tests are performed near the patient rather than in a central laboratory: rapid antigen tests, blood glucose meters, portable blood gas analysers, and handheld ultrasound. They shorten time to result and extend testing to settings without laboratory infrastructure, at the cost, usually, of some analytical performance and of the quality-control systems a laboratory provides. In many contexts a faster, somewhat less accurate result that changes management immediately is more useful than a more accurate one that arrives too late.

Digital and Algorithmic Diagnostics

Software increasingly participates in diagnosis: algorithms analysing images, electrocardiograms, or continuous monitoring data; digital pathology systems supporting slide review; and clinical decision support tools. Where such software is intended for a medical purpose it is generally regulated as a medical device, and current practice positions these tools as support for clinician judgement.

How Diagnostic Accuracy Is Measured

Sensitivity and Specificity

Sensitivity is the proportion of people who have the condition whom the test correctly identifies. A highly sensitive test produces few false negatives and is therefore useful for ruling a condition out when the result is negative.

Specificity is the proportion of people without the condition whom the test correctly excludes. A highly specific test produces few false positives and is therefore useful for ruling a condition in when the result is positive.

These properties trade off against each other. Adjusting the threshold at which a test is called positive increases one at the expense of the other, and the appropriate balance depends on the clinical consequences of each type of error.

Predictive Values and Prevalence

Sensitivity and specificity describe the test. Predictive values describe what a result means for a particular person, and they depend on how common the condition is in the population being tested.

The same test applied to a symptomatic patient in a specialist clinic and to an asymptomatic person in a general screening programme produces very different positive predictive values. Where the condition is rare, even a specific test generates many false positives, because the small proportion of false positives among a very large number of unaffected people can outnumber the true positives among the few affected. This is the central reason that a good test can be inappropriate for population screening.

Other Measures

Likelihood ratios express how much a result shifts the probability of disease and combine sensitivity and specificity into a form usable with pre-test probability. Analytical performance measures — precision, accuracy, limit of detection, and interference — describe how the assay behaves as a measurement, distinct from how well it discriminates disease.

How Diagnostics Are Used Clinically

  • Diagnosis: establishing the cause of symptoms.
  • Screening: testing people without symptoms to detect disease earlier.
  • Monitoring: tracking disease activity or treatment response over time.
  • Prognosis: estimating likely course and outcome.
  • Treatment selection: identifying which therapy is most likely to work, including through companion diagnostics.
  • Risk assessment: estimating future probability of disease, including through genetic testing.

Companion Diagnostics and Precision Medicine

A companion diagnostic is a test required to identify patients who are likely to benefit from a specific therapy, or who are at increased risk of harm from it. These tests are developed alongside the medicine and are often co-approved with it. They are central to targeted cancer therapy, where treatment selection may depend on the presence of a specific molecular alteration, and to pharmacogenomics, where genetic variation in drug metabolism informs dosing or drug choice.

Screening: A Different Standard of Evidence

Screening applies tests to people without symptoms, most of whom do not have the condition. The evidentiary bar is therefore higher than for diagnostic testing, because harms are imposed on healthy people.

Established criteria for a sound screening programme include: the condition should be an important health problem with a recognisable early stage; effective treatment should exist and early treatment should improve outcomes; a suitable, acceptable test should be available; and the programme's benefits should outweigh its harms and costs, with quality assurance and equitable access built in.

Specific harms merit explicit attention. Overdiagnosis is the detection of disease that would never have caused symptoms or harm in a person's lifetime, leading to treatment that can only cause harm. False positives generate anxiety, further investigation, and procedural risk. False negatives may create false reassurance. Lead time bias can make earlier detection appear to prolong survival when it has only advanced the moment of diagnosis. These are the reasons screening decisions rest on randomized evidence of mortality or morbidity benefit rather than on detection rates.

Regulation and Quality

In vitro diagnostics are regulated as medical devices, with requirements scaled to risk. In the European Union, the In Vitro Diagnostic Regulation classifies tests from Class A to D and requires notified body involvement for most categories. In the United States, in vitro diagnostics are regulated by the FDA through device pathways, and laboratory operations are additionally subject to laboratory certification requirements.

Laboratory quality systems provide a second layer of assurance: internal quality control run alongside patient samples, external quality assessment through proficiency testing against other laboratories, accreditation to international standards, method validation before a test enters routine use, and traceability of results to reference materials where these exist. Pre-analytical factors — how a sample is collected, labelled, transported, and stored — are a well-documented source of error and receive corresponding attention.

Challenges in Diagnostics

  • Access. Laboratory infrastructure, trained personnel, reagent supply chains, and cold chain requirements limit availability in many settings; WHO maintains a list of essential in vitro diagnostics to support prioritisation.
  • Antimicrobial resistance. Rapid diagnostics that distinguish bacterial from viral infection and identify resistance patterns are needed to support appropriate prescribing.
  • Incidental findings. Broad genomic and imaging tests generate findings of uncertain significance, requiring interpretation frameworks and consent processes that anticipate them.
  • Evidence for algorithmic tools. Diagnostic algorithms require validation in populations representative of intended use, and performance can degrade when data or practice shift.
  • Overtesting. Testing without a clear question generates incidental findings, cost, and cascades of further investigation, and is a recognised quality problem in its own right.

Sources

  • World Health Organization — Essential Diagnostics List; screening principles and guidance
  • U.S. Food and Drug Administration — in vitro diagnostics and companion diagnostic regulation
  • European Union In Vitro Diagnostic Regulation — classification and conformity assessment
  • International Organization for Standardization — ISO 15189 medical laboratory quality standards
  • Cochrane — diagnostic test accuracy review methodology
  • STARD Statement — reporting standards for diagnostic accuracy studies